A historical sketch of the discovery and development of HIV-1 integrase inhibitors

@article{Savarino2006AHS,
  title={A historical sketch of the discovery and development of HIV-1 integrase inhibitors},
  author={Andrea Savarino},
  journal={Expert Opinion on Investigational Drugs},
  year={2006},
  volume={15},
  pages={1507 - 1522}
}
  • A. Savarino
  • Published 15 November 2006
  • Biology, Medicine
  • Expert Opinion on Investigational Drugs
The long process of HIV-1 integrase inhibitor discovery and development can be attributed to both the complexity of HIV-1 integration and poor ‘integration’ of these researches into mainstream investigations on antiretroviral therapy in the mid-1990s. Of note, some fungal extracts investigated during this period contain the β-hydroxyketo group, later recognised to be a key structural requirement for keto-enol acids (also referred to as diketo acids) and other integrase inhibitors. This review… Expand
HIV-1 integrase inhibitors: update and perspectives.
TLDR
The chapter presents an overview of the functions of IN and the cofactors for integration and presents list of the known mutations that have been characterized for HIV‐1 integrase (IN) with their impact on IN activity, viral replication, and response to anti‐IN drugs. Expand
Authentic HIV-1 integrase inhibitors.
TLDR
A number of patented HIV-1 IN inhibitors, especially those that possess high selectivity for the strand transfer reaction, are reviewed, particularly those that have a polar coplanar moiety. Expand
HIV-1 Integrase Inhibitors
TLDR
The results from advanced stages of human clinical trials with HIV-1 integrase (IN) inhibitors indicate a promising future for these compounds as a novel class of antiretroviral drugs. Expand
HIV-1 Integrase Strand Transfer Inhibitors
TLDR
The chapter presents a brief synopsis on the biological role of DNA integration during the retroviral viral life cycle with a focus on the bond-making and -breaking biochemical steps and discusses the reasons that make these amenable to inhibition. Expand
Anti-infectives Clinical progress of HIV-1 integrase inhibitors
TLDR
The development of strand transfer-specific inhibitor classes is an important achievement for the IN drug design and development field, but continued drug development is needed given that the ability of HIV to replicate under therapeutic pressure will undoubtedly lead to the emergence of IN drug-resistant viral strains. Expand
Development and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain of HIV-1 Integrase
TLDR
Results confirmed peptide 25 as a hit for further development of new chemotherapeutic agents against HIV-1 and identified two nonapeptides, that show a potency of inhibition similar to the one of peptide 18. Expand
HIV‐1 integrase inhibitors: 2005–2006 update
TLDR
A comprehensive report of all IN inhibitors discovered in the years 2005 and 2006 is provided to provide a continued effort toward the discovery of novel inhibitors to keep a therapeutic advantage over the virus. Expand
Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor
TLDR
A dibenzocyclooctadiene lignan, termed HDS2 was identified that possessed anti-HIV activity against a wide variety of viral strains with EC50 values in the 1–3 µM range and provides a new scaffold for further optimization of activity through structure-guided design. Expand
New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action
TLDR
It is shown that in addition to the properties already known for LEDGINs, the binding of tBPQAs to the IN dimer interface inhibits IN enzymatic activity in a LEDGF-independent manner, and this inhibition occurs at or prior to the viral DNA 3′-processing step. Expand
Naphthoxazepine Inhibitors of HIV‐1 Integrase: Synthesis and Biological Evaluation
TLDR
Two sets of compounds derived from the fusion of a diversely annulated naphthoxazepinedione system with 1,3‐thiazole and 1, 3‐oxazole are described, gaining further insight into the structure–activity relationship of this class of IN inhibitors. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 122 REFERENCES
Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga
TLDR
The first review of the entire patent literature for small molecule intergrase inhibitors is presented, based on compounds with potential to serve as leads, therefore, no attempts are made to include: antibodies, oligonucleotides or polypeptides. Expand
Design and development of integrase inhibitors as anti-HIV agents.
TLDR
A review is presented on different categories of compounds that have been studied for the inhibition of the HIV-1 integrase to develop anti-HIV agents and the important structural features essential for the inhibitor of the integrase are pointed out. Expand
Integrase inhibitors to treat HIV/Aids
TLDR
This review focuses on the molecular basis and rationale for developing integrase inhibitors, as well as the main classes of lead compounds and interfacial inhibitors of protein–nucleic-acid interactions that might apply to the clinically used strand-transfer inhibitors. Expand
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.
TLDR
The modification of a quinolone antibiotic is described to produce the novel integrase inhibitor JTK-303 (GS 9137) that blocks strand transfer by the viral enzyme. Expand
Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
HIV-1 integrase is an essential enzyme for retroviral replication. It is involved in the integration of HIV DNA into host chromosomal DNA and appears to have no functional equivalent in human cells.Expand
Patented HIV-1 integrase inhibitors (1998-2005).
  • P. Cotelle
  • Biology, Medicine
  • Recent patents on anti-infective drug discovery
  • 2006
TLDR
The present article reviews the increasing number of patents on small molecule HIV-1 integrase inhibitors in the 1998-2005 period, from the pioneer ones (discovery of selective strand transfer inhibitors) to the last patents including the actual molecules under clinical trials. Expand
Discovery of natural product inhibitors of HIV-1 integrase at Merck
TLDR
The evaluation of over 200,000 extracts originating from more than 50,000 microbial strains equally represented by fungi and actinomycetes led to the discovery of 24 novel classes of chemically diverse natural product inhibitors of HIV-1 integrase, representing a wide variety of classes with molecular weights ranging from 180-1,663 Da and HIV- 1 integrase-inhibitory activity IC 5 0 values ranging from 50 nM to > 100 μM. Expand
HIV‐1 integrase inhibitors: 2005–2006 update
TLDR
A comprehensive report of all IN inhibitors discovered in the years 2005 and 2006 is provided to provide a continued effort toward the discovery of novel inhibitors to keep a therapeutic advantage over the virus. Expand
Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.
TLDR
Peptides deriving from the HIV-1 HXB2 Pol gene sequence may potentially be used in the elucidation of structural and functional epitopes of IN involved in protein-protein and protein-small molecule interactions. Expand
Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design.
TLDR
The structure of a complex of the HIV-1 integrase core domain with a novel inhibitor, 5ClTEP, 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-5-yl)pro penone, to 2.1-A resolution is determined. Expand
...
1
2
3
4
5
...